PHILADELPHIA — A choroidal melanoma therapy has been shown to reduce tumor thickness and preserve best corrected visual acuity in patients participating in a phase 1b/2 study, according to a speaker here.
AU-011 (Aura Biosciences) has been administered to 30 patients with choroidal melanoma, demonstrating 87% tumor control in subjects with a single cycle treatment up to 6 months, Carol L. Shields, MD, said at the Wills Eye Conference.
“This is a safe treatment for both single and multiple administrations. Inflammation is manageable, and we have seen reduction in tumor (Read more...)
Uncategorized